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The main objective of the present study was to determine the permeability of clarithromycin (CLA)-PLGA 
nanoparticles using single-pass intestinal perfusion technique in rats. Clarithromycin nanoparticles were 
prepared by nano-precipitation according to the modified quasi emulsion solvent diffusion technique and 
evaluated for their physicochemical characteristics. Permeability coefficients (Peff) in anaesthetized rats 
were determined at 3 different concentrations. Drug solution or suspensions in PBS was perfused through 
a cannulated jejunal segment and samples were taken from outlet tubing at different time points up to 
90 min. Microbiological assay of CLA and phenol red in the samples were analyzed using an agar well 
diffusion procedure and HPLC method respectively. The average particle size of prepared nanoparticles 
was 305 ± 134 nm. The mean Peff of CLA solution in concentrations of 150, 250 and 400 µg/mL was 
found to be 1.20 (±0.32) ×10-3, 9.62 (±0.46) ×10-4, and 1.36 (±0.95) ×10-3 cm/sec, respectively. The 
corresponding values for the same concentration of nanoparticles were found to be 2.74 (±0.73) ×10-3, 
2.45 (±0.88) ×10-3, and 3.68 (±0.46) ×10-3 cm/s, respectively. The two-tailed Student’s t-test showed that 
the intestinal permeability of CLA nanoparticle suspensions in prepared concentrations were significantly 
increased in comparison with its solution.
Uniterms: Clarithromycin/nanoparticles/ permeability. Single-Pass Intestinal Perfusion. Intestinal 
permeability.
O objetivo principal do presente estudo foi determinar a permeabilidade de nanopartículas de claritromicina 
(CLA)-PLGA, utilizando a técnica de perfusão intestinal de passo único em ratos. As nanopartículas 
de claritromicina foram preparadas por nanoprecipitação, de acordo com a técnica modificada de 
difusão de solvente quase-emulsão, e suas características físico-químicas avaliadas. Os coeficientes de 
permeabilidade (Peff) em ratos anestesiados foram determinados em três concentrações diferentes. A 
solução, ou suspensões, do fármaco em PBS foi perfundida através do segmento de jejuno canulado e as 
amostras foram tomadas do tubo externo em diferentes tempos até 90 minutos. Os ensaios microbiológico 
de CLA e de vermelho de fenol das amostras foram realizados, utilizando-se o procedimento de difusão 
em poço de ágar e de CLAE, respectivamente. O tamanho médio das partículas das nanopartículas 
preparadas foi de 305 ± 134 nm. O Peff médio da solução de CLA em concentrações de 150, 250 and  
400 µg/mL foi de 1.20(±0.32)×10-3, 9.62(±0.46)]×10-4 e de 1.36(±0.95)×10-3 cm/s, respectivamente. 
O valor correspondente para a mesma concentração de nanopartículas foi de 2.74 (±0.73)×10-3, 
2.45(±0.88)×10-3 e de 3.68 (±0.46)×10-3 cm/s, respectivamente. O teste t de Student com duas variáveis 
mostrou que a permeabilidade intestinal das suspensões de nanopartículas de CLA nas concentrações 
preparadas foram significativamente aumentadas em comparação com sua solução. 
Unitermos: Claritromicina/nanopartículas/permeabilidade. Perfusão Intestinal de Único Passo. 
Permeabilidade intestinal.
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INTRODUCTION
Oral administration remains the most convenient 
and useful route for delivering most pharmaceutical 
agents. However, the major problem of many orally 
administered drugs is to overcome several barriers 
before reaching their target site (Cook, Shenoy, 2003; 
Rao et al., 2008). Several approaches have been applied 
in order to improve the oral bioavailability of poorly 
permeable and soluble compounds intended for oral 
administration. Using nanoparticulate drug delivery 
system is considered as one of these strategies (Cai et 
al., 2010; Saha et al., 2010). These formulations have 
been shown to be efficient approaches to enhance the 
transport of a large number of drugs including nucleic 
acids and genes across many biological membranes as 
well as to improve the stability of these materials. This 
could result in enhanced oral bioavailability of poorly 
bioavailable drugs due to their specialized uptake 
mechanisms such as circumventing the P-gp efflux and 
protecting incorporated drug molecules from the gastro-
intestinal tract (GIT) degradation as well as gut wall and 
first pass metabolism (Arayne, Sultana, 2006; Florence, 
2004; Moinard-Checot et al., 2006). Since the intestinal 
epithelium is one of the main obstacles the drugs should 
pass through, it is both a great interest and a medical 
need for improving the intestinal permeability of various 
poorly bioavailable drugs. Intestinal permeability or 
the ability of a compound to move across the intestinal 
epithelial barrier is an important and critical determinant 
of its rate and extent of absorption (Zakeri-Milani et al., 
2009a; Zakeri-Milani et al., 2007). A number of different 
in vivo, in situ and in vitro methods have emerged to 
determine the intestinal permeability of drugs and their 
mechanism of absorption. These include diffusion studies 
with intestinal segments from various species (e.g. rat 
and rabbit) or with cultured cell monolayers (e.g. Caco-2 
cells); uptake studies in brush-border membrane vesicles 
prepared from intestinal segments of various species; 
and the single-pass intestinal perfusion (SPIP) in small 
mammals, most commonly rats (Artursson, Karlsson, 
1991; Hillgren et al., 1995; Salphati et al., 2001). 
Among these, single-pass intestinal perfusion (SPIP) 
provides conditions closer to what is faced following 
oral administration (Cook, Shenoy, 2003; Jeong et al., 
2004). This technique has low sensitivity to pH variations 
due to the preserved microclimate above the epithelial 
cells, and it maintains an intact blood supply to the 
intestine as well as providing the unique advantages 
of experimental control (e.g. compound concentration 
and intestinal perfusion rate), and the ability to study 
regional differences (Song et al., 2006; Wu et al., 2004; 
Zakeri-Milani et al., 2009b). Clarithromycin (CLA) 
6-O-methylerythromycin, is a semi-synthetic macrolide 
antibiotic with a broad antibacterial spectrum which 
is used in many infectious conditions like upper and 
lower respiratory tracts infections, skin, ear and other 
soft tissues infections, caused by different bacterial 
groups (Alkhalidi et al., 2008; Gomez-Burgaz et al., 
2009; Lu et al., 2008). Clarithromycin is also the drug 
of choice to treat peptic ulcer as H. pylori resistance 
rate is much lower for clarithromycin as compared to 
other antibiotics like amoxicillin and tetracycline (Jain 
et al., 2006; Zakeri-Milani et al., 2005). However, 
like many other macrolide antibiotics, clarithromycin 
exhibits poor absorption and low bioavailability when 
administered orally (Inoue et al., 2007). It is extensively 
metabolized by CYP3A (which is highly expressed in 
the gastrointestinal tract) to 14-hydroxyclarithromycin 
and N-desmethylclarithromycin and exhibits nonlinear 
pharmacokinetics, demonstrated by reduced clearance 
with increasing doses. Although these metabolites may 
also inactivate CYP3A, they occur at low systemic 
concentrations in vivo such that circulating metabolites 
will probably have an insignificant effect on CYP3A 
(Quinney et al., 2010). Therefore it is desirable to design 
CLA-loaded biodegradable nanoparticles with improved 
physicochemical properties and antibacterial activity 
against intracellular bacteria as well as an enhanced 
intestinal permeability and thereafter an increased 
bioavailability. The objective of the present study 
was to determine the permeability of clarithromycin 
previously (Mohammadi et al., 2011) prepared as PLGA 
nanoparticles in comparison with pure drug solution 
using single-pass intestinal perfusion technique in rats 
and to investigate whether a nanoparticulate formulation 
could improve intestinal permeability of the compound.
MATHERIAL AND METHODS
Material
Clarithromycin powder was obtained from Dr 
Reddy’s Pharmaceutical Company, India. Poly (d,l-
lactide-co-glycolide) (PLGA) (50:50 d,l-lactide:glycolide) 
with average molecular weight of 12,000 g/mol (Resomer 
RG 502), was purchased from Boehringer Ingelheim, 
Germany. Micrococcus luteus ATCC 9341 was purchased 
from Pasteur Institute, Iran. Poly vinyl alcohol, PVA, 
with molecular weight of 95000 (Acros Organics, Geel, 
Belgium) were used. Phenol red was purchased from 
Sigma Chemical Co. (St. Louis, MO). KH2PO4, NaH2PO4, 
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Na2HPO4, Orthophosphoric acid, NaOH, and NaCI were 
purchased from Merck (Darmstadt, Germany). All other 
materials were of analytical or HPLC grade and obtained 
from Merck (Darmstadt, Germany).
Preparation of solutions
The perfusion buffer consisted of 5.77 g/L Na2HPO4 
(anhydrous), 4.085 g/L NaH2PO4.2H2O, and 7 g/L NaCl. 
The pH of prepared buffer was adjusted to 7.2. Phenol 
red (0.7 mM) and metoprolol (0.07 mM) were added to 
the solution in all experiments as non-absorbable marker 
and internal standard respectively. Phenol red (0.7 mM) 
was added to the solution as a non-absorbable marker in 
all experiments. Control drug solutions were prepared 
in perfusion buffer (PBS) to obtain clarithromycin 
concentrations of 150, 250 and 400 µg/mL.
Preparation of nanoparticles
Nanoparticles were prepared by nano-precipitation 
according to the modified quasi emulsion solvent 
diffusion technique. CLA and PLGA powders (with 1:3 
ratio) were co-dissolved in internal phase containing 
acetone, 2.5 mL, at room temperature (25 °C). The 
resulting organic solution was injected at the constant 
rate of 0.5 mL/min in aqueous phase (40 mL) containing 
PVA 95000 (2% w/v), as a stabilizing agent (Salem, 
Duzgunes, 2003). The process was carried out under 
homogenization for 5 min using the Silent Crusher M 
(Heidolph, Germany). The agitation speed was 13000 
rpm in an ice-water bath. Organic phase was eliminated 
at room temperature under stirring for 12 hours. The final 
nano-suspension was centrifuged (Beckman Centrifuge, 
AvantiTMJ-25, USA) at 14000 rpm for 30 min and the 
precipitated nanoparticles were washed twice with water, 
using the previously described centrifugation approach, 
and then lyophilized using a lyophilizer (Christ Alpha 
1-4; Germany). Final dry powder was taken out for 
further investigations. The nanoparticle suspensions were 
prepared to obtain concentrations of 150, 250 and 400 
µg/mL (Mohammadi et al., 2011).
Physicochemical evaluation of nanoparticles
Evaluation of the physicochemical properties of the 
prepared nanoparticles was performed using encapsulation 
efficiency and dissolution studies, particle size analysis, 
zeta potential determination, differential scanning 
calorimetry and Fourier-transform infrared spectroscopy. 
The nanoparticle production yield was determined from 
the mass ratio of the prepared nanoparticle to the initially 
added PLGA and drug (Zakeri-Milani et al., 2013). The 
experiment was carried out using 3 samples equivalent to 
5 mg drug. The mean particle-size values were measured 
using a laser diffraction particle-size analyzer (Sald 2101, 
Shimadzu, Japan) equipped with Wing software (version 
1.20). Scanning electron microscopy (SEM) (LEO 440i, 
Leo Electron Microscopy Ltd., Cambridge, UK) at an 
accelerating voltage of 20 kV was used to examine the 
morphology of the nanoparticles. The particle surface 
charge was quantified as zeta potential using a Zetasizer 
4 (Malvern Instr., UK). Thermograms of CLA, PLGA, 
nanoparticles and corresponding physical mixture of 
the drug with the polymer were recorded on a DSC-
60 (Shimadzu, Kyoto, Japan). For drug release study, 
the prepared nanoparticles were placed in the vessels 
containing 250 mL phosphate buffer (pH 6). The vessels 
were incubated at 37oC with continuous orbital mixing 
(50 rpm). At specified time intervals, 3 mL of medium 
was removed using a glass syringe fitted to cellulose 
acetate membrane, 25 mm diameter and 20 nm pore 
diameter (Whatman, UK). After each sampling, an equal 
volume of fresh dissolution media was passed through 
the same filtration assembly to replace the withdrawn 
aliquots. The cumulative amount of the released CLA 
was calculated considering the replaced volume of the 
dissolution medium and the cumulative percentage of 
the released drug was plotted versus time. The mean 
calculated values were obtained from 3 replicates 
(Mohammadi et al., 2011).
Single-pass intestinal perfusion experiment
Single-pass intestinal perfusion (SPIP) studies 
were performed according to the previously established 
methods (Jeong et al., 2004; Salphati et al., 2001; Zakeri-
Milani et al., 2007, 2008, 2009a). Briefly, male Wistar 
rats (250-300 g) were maintained on a 12 h light-dark 
cycle and fasted 12-18 h overnight before the experiment. 
Drinking water was readily accessible. After anesthesia 
via intra-peritoneal administration of pentobarbital (60 
mg/kg), rats were placed on a heating pad to maintain 
body temperature at 37 °C. Upon verification of the 
loss of pain reflex the abdomen was opened by a 3-4 
cm midline longitudinal abdominal incision and a 10 
cm section of the proximal rat jejunum was located, 
isolated and cannulated at both ends with plastic tubing. 
Then the intestinal segment was gently rinsed with 
saline (37 °C) and attached to the perfusion assembly. 
Blank perfusion buffer was infused for 10 min by a 
syringe pump (Palmer, UK), followed by perfusion of 
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the clarithromycin solution or nanoparticle suspension 
in 3 different concentrations at a flow rate of 0.2 mL/
min for 90 min. The outlet samples were collected every 
10 minutes, frozen immediately and stored at -20 °C 
until analysis. The length of the perfused segment was 
measured at the end of the experiment and the animal was 
euthanized with a cardiac injection of a saturated solution 
of KCl. In all animal studies, The Guide to the care and 
use of experimental animals by the Canadian council on 
animal care was followed.
Microbial analysis of clarithromycin in the 
samples
Microorganism and inoculums standardization
Micrococcus luteus ATCC 9341 was purchased in 
lyophilized form (Pasteur Institute, Iran) and activated 
in trypticase soy broth medium. Fifty microliters of the 
growth medium was transferred into antibiotic agar 
medium I (24 h before assay) and incubated at 35 °C for 
one day. The bacterial growth culture was diluted with a 
0.9% w/v saline solution, in order to reach 30% turbidity 
at 580 nm, and the resultant bacterial suspension was then 
used as culturing inoculums.
Well diffusion assay
Microbiological assay of clarithromycin in the 
samples was performed using an agar well diffusion 
procedure (USP, 2008). Briefly, the assay plate contained 
25 mL of antibiotic agar I inoculated with the bacterial 
inoculums. Wells of 6mm diameter were punched 
and filled with 100 µL of calibration samples or test 
samples. After 24 h of incubation at 35 °C, the diameter 
of the inhibition zone was measured. The method was 
validated by determination of the following operational 
characteristics: linearity, precision and accuracy 
(Mohammadi et al., 2011). The linearity was evaluated 
using the linear regression analysis which was calculated 
by the least squares regression method. Clarithromycin 
calibration standards were prepared at concentrations of 
500, 450, 350, 250, 150 and 50 µg/mL. Each level was 
made in triplicate and employed on the well diffusion 
assay method described above. The precision of the 
assay method was determined by evaluating repeatability 
(intra-assay) and intermediate precision (inter-assay), and 
expressed as the relative standard deviation (RSD) of four 
quality control samples. The accuracy was determined 
by adding known amounts of clarithromycin reference 
substance (quality control samples) at the beginning of the 
process, followed by calculation of the value: measured 
value/nominal value × 100.
Liquid chromatographic conditions for analysis of 
phenol red
For analysis of phenol red in the samples, Shimadzu 
HPLC system (Shimadzu, Kyoto, Japan) comprising an 
LC-10ADvp pump and a variable wavelength ultraviolet 
spectrophotometric detector (SPD-10Avp) set at 430 nm 
was used.
The phenol red concentrations in the perfusion 
buffer were determined using a previously developed 
HPLC method in which the mobile phase consisting of a 
mixture of 55% methanol and 45% of 0.05 mol/L KH2P04 
aqueous solution (adjusted to pH 2.6) was pumped into a 
Shimpack VP-ODS 5 µm 4.6 × 250 mm with a Shimpack 
VP-ODS 5 µm 4.6 ×50 mm guard column at a flow rate 
of 1 mL/min. Under these conditions the phenol red 
retention time was found to be 3 min (Swenson et al., 
1994; Valizadeh et al., 2006; Zakeri-Milani et al., 2005). 
Class VP software was used for data acquisition and 
processing.
Data Analysis
Effective permeability coefficients (Peff) were calcu-
lated after correcting the steady-state outlet concentra-
tions for water flux based on the ratio of inlet and outlet 
concentrations of an un-absorbable marker, phenol red. 
The SPIP technique performed in the present study for 
estimating intestinal permeability coefficient uses a mass 
balance approach. Two models namely Well-stirred model 
(i.e. mixing tank model) and Parallel tube model (i.e. 
complete radial mixing model) are used to explain this 
approach. Steady state was reached about 40 min after the 
beginning of the perfusion and was confirmed by plotting 
the ratio of the outlet to inlet concentrations versus time. 
The representative results for CLA 250 μg/mL in perfusion 
solution are plotted in Figure 1. Assuming the parallel tube 
model, the Peff values were calculated using the following 
equation:
Peff= -Qin [Cout/Cin]/2πrl
where Q is the perfusion buffer flow rate (0.2 mL/ min), 
Cout/Cin is the ratio of the outlet concentration and inlet 
concentration of clarithromycin that has been adjusted 
for water transport during the perfusion, r is the radius of 
the intestinal segment (0.18 cm) and l is the length of the 
intestinal segment. Values were indicated as mean ± SD for 
permeability in four independent rats. Statistical difference 
between the permeabilities of different concentrations of 
clarithromycin in the form of solution and nanoparticle 
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suspension was evaluated by two-tailed Student’s t-test. 
P-values<0.05 were considered significant.
RESULTS AND DISCUSSION
Micrococcus luteus was selected for performing the 
antibacterial assay as it is a non-pathogenic bacterium and 
has good sensitivity to clarithromycin (Mohammadi et al., 
2011). The six point linearity curves for clarithromycin 
were constructed in the range of 50-500 µg/mL. These 
concentration ranges were selected based on the drug 
concentrations used in the permeability studies. The 
regression analysis of the obtained responses generated 
a linear curve with a correlation coefficient of 0.992. 
Nanoparticles with efficient loading of clarithromycin and 
submicron size range were obtained. Loading efficiencies 
of the obtained particles were calculated using the equation 
shown below:
Loading efficiency (%) = (actual drug content in nano-
particles/theoretical drug content) × 100.
Loading efficiencies for three different concen-
trations of drug (400, 250 and 150 µg/mL) were between 
71.78% - 98.8% (Table I). Poor entrapment of drug in 
the applied concentration of 400 µg/mL could be due 
to the low aqueous solubility of both polymer and CLA 
(practically insoluble) in water. Higher loading efficiency 
was obtained with decreasing the initially applied amount 
of the drug.
According to the results of particle size analysis 
and SEM studies (Figure 1), the obtained nanoparticles 
were between 200 to 500 nm in size with narrow size 
distribution, and spherical shape. The mean particle size 
was found to be 305 ± 134 nm.
Zeta potential of the nanoparticles, intact polymer 
and CLA were -20.32 ± 2.84 and 1.47 ± 1.61, and -14.26 
± 1.92 mV, respectively. Intact CLA powder had an 
endothermic peak corresponding to its melting point at 
231.34 oC, there was no distinct CLA melting endotherm 
in the nanoparticle, suggesting a complete amorphization 
of the drug in the prepared nanoparticles (Figure 2).
TABLE I - Loading efficiency of different CLA concentrations loaded in PLGA nanoparticles
Initially applied drug 
concentration (µg/mL)
diameter of the inhibition 
zone (mm)
Measured drug concentration 
(µg/mL)
Loading efficiency (%)
400 24.76 287.1 71.78%
250 23.85 247.3 98.92%
150 21.58 148.2 98.80%
FIGURE 1 - SEM image of clarithromycin loaded nanoparticles 
of 1:3 drug to polymer ratio.
FIGURE 2 - DSC curves of the intact clarithromycin (CLA), 
PLGA, their physical mixture (PM) and clarithromycin loaded 
nanoparticles (NANO) of 1:3 drug to polymer ratio.
The time required for 50% of drug dissolved (t50%) 
which is inversely related to the dissolution rate are 30 
min for CLA and 180 min for nanoparticles. The presence 
of insoluble polymer in the nanoparticles matrix body 
reduces the water penetration, hence dissolution and 
diffusion. A very slow release pattern for nanoparticles 
was seen after an initial burst within 4 h. 59% of drug 
was released during the first 4 hours from nanoparticles. 
This may be attributed to the dissolution of the drug that is 
poorly entrapped in the polymer matrix, while the slower 
and continuous release may be ascribed to the diffusion of 
the drug localized in the PLGA core of the nanoparticles. 
In SPIP experiments steady state was reached about 40 
min after the beginning of the perfusion and was confirmed 
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by plotting the ratio of the outlet to inlet concentrations 
versus time. The representative results for CLA 250 μg/mL 
 in perfusion solution are plotted in Figure 3.
The intestinal permeability of clarithromycin in three 
different concentrations was determined in rat jejunum using 
the in situ single-pass perfusion technique. The samples 
were analyzed by the above mentioned method. Prior to the 
in situ study, stability assessment was performed to evaluate 
the stability of the test drug in blank perfusion samples by 
simulating the same conditions which occurred during the 
study. The results showed that drug was sufficiently stable 
throughout the duration of experiment (120 min) in all 
investigated solutions. The mean effective permeability 
coefficients of clarithromycin solution in concentrations of 
150, 250 and 400 µg/mL in perfusion solution were found 
to be 1.20(±0.32)×10-3 cm/s, 9.62(±0.46)×10-4 cm/s, and 
1.36(±0.946)×10-3 cm/s respectively. The corresponding 
values at the same concentration of nanoparticles were 
found to be 2.74(±073)×10-3 cm/s, 2.45(±0. 877)×10-3 cm/s, 
and 3.68(±0.46)×10-3 cm/s respectively. The effective 
permeability of clarithromycin from nanoparticle 
suspension was 2.28 fold enhanced in comparison to the 
solution form at the concentration of 150 µg/mL whereas 
these enhancement ratios were 2.54 and 2.70 in the case of 
250 and 400 µg/mL samples, respectively. The obtained 
data suggests a slight increase in the enhancement ratio by 
increasing the concentration of drug within nanoparticles. 
As it is shown in Figure 4, the two-tailed Student’s t-test 
showed that the intestinal permeability of clarithromycin 
was significantly increased in the nanoparticle suspension 
form in all four clarithromycin concentrations used 
(P < 0.05).
This finding is in agreement with the previously 
published literature about the intestinal uptake of nano 
sized particles. For instance in one study the results of 
in vitro permeation experiments by Ussing chambers 
has shown that the permeability of tacrolimus was 
enhanced significantly in the form of nanoparticles 
in comparison with its solution in both healthy and 
inflamed tissues (Lamprecht et al., 2005). In another 
study, PLGA nanoparticles loaded with curcumin was 
designed and prepared and the comparison of in situ 
intestinal permeability and also the bioavailability of 
these nanoparticles with that of native curcumin showed 
that encapsulating the drug in PLGA polymers could 
enhance its intestinal permeability as well as its in vivo 
bioavailability (Xie et al., 2011). In a similar study, 
the cyclosporine nanoparticles showed significantly 
higher intestinal uptake of around 90% as compared to 
Sandimmune Neoral®, which showed around 55% and 
Cyclosporine sodium CMC suspension with an uptake of 
only 10% (Italia et al., 2007).
It has been demonstrated that the effect of delivering 
the drug in the nanoparticle form on bioavailability are 
primarily based on the fundamentals that nanonization 
increases the contact surface area of drugs. Drug 
nanonization would result in an increase in adhesion 
surface area between intestinal epithelial cells and 
nanoparticles as well as an increased dissolution rate 
and also an increase in saturation solubility that favors 
increased concentration gradient between intestinal 
epithelial cells and the mesenteric circulation beneath 
(Mohanraj, Chen, 2006). The results of such studies 
showed that PLGA may have bioadhesive properties and 
bind with the mucosa of the gastrointestinal tract. This may 
increase the residency time and enhance drug absorption 
due to intimate contact with epithelium cells. It was also 
reported that PLGA as a drug carrier moderates the P-gp 
FIGURE 3- Plot of concentration ratio of the inlet and outlet 
tubing (Cin/Cout) vs. time for CLA (250 μg/mL) perfusion study 
(n=4, error bars represent SD).
FIGURE 4 - Intestinal permeability of clarithromycin in control 
and test samples at three concentration levels. Values are the 
mean ± SD of four determinations.
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effect and MDR reversal activity, however, the P-gp 
inhibition mechanism of PLGA, which mainly involves 
changing the fluidity of the cellular membrane, inhibiting 
P-gp ATPase, and reducing P-gp expression, remains 
unclear (Xie et al., 2011). In general, the gastrointestinal 
absorption of macromolecules and particulate materials 
involves either paracellular route or endocytotic 
pathway. Using polymers such as chitosan, starch or poly 
(acrylate) can increase the paracellular permeability of 
macromolecules. Endocytotic pathway for absorption of 
nanoparticles is either by receptor-mediated endocytosis, 
that is, active targeting, or adsorptive endocytosis which 
does not need any ligands. This process is initiated by 
an unspecific physical adsorption of material to the cell 
surface by electrostatic forces such as hydrogen bonding or 
hydrophobic interactions. Adsorptive endocytosis depends 
primarily on the size and surface properties of the material. 
This shows that a combination of size, surface charge and 
hydrophilicity play a major role in affinity (Damge et al., 
1996; Kotze et al., 1998; Win, Feng, 2005).
Although clarithromycin exhibits undesirable 
physicochemical and biopharmaceutical properties (e.g., 
large molecular weight, extensive potential for hydrogen 
bonding, high polar surface area, substrates for efflux 
transporter P-glycoprotein), based on the obtained results 
it showed high intestinal permeability in rats. The drug 
was previously reported to have moderate to excellent 
oral bioavailability in preclinical species and humans (Lan 
et al., 2009). A potential explanation for this paradox is 
that intestinal transporters may facilitate CLA absorption. 
Previous studies in rats suggested that oral absorption of 
azithromycin and clarithromycin is mediated by an Oatp 
and/or other rifamycin SV-sensitive intestinal transporter 
(Garver et al., 2008). This indicates that the drug may be 
involved in active transport mechanisms which causes the 
drug fell outside the lipiniski ‘rule of 5’ (Doppenschmitt 
et al., 1999).
CONCLUSION
The results of the present study suggest that 
formulating clarithromycin as nanoparticles, could 
improve its intestinal permeability in comparison with 
the pure drug solution. This could be at least partly, due 
to the contribution of PLGA in alteration of the intestinal 
permeability.
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